Press Releases

Sign up for Email Alerts Press Release RSS

01/02/2019
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Term:Corporate/Financial News
Language:English
12/19/2018
Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical Holdings Co., Ltd to Purchase UPSA
Term:Bristol-Myers
Language:English
12/17/2018
Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance
Term:Corporate/Financial News
Language:English
12/17/2018
Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform
Term:R&D News
Language:English
12/17/2018
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Term:Corporate/Financial News
Language:English
12/10/2018
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
Term:R&D News
Language:English
12/06/2018
Bristol-Myers Squibb Announces Dividend Increase
Term:Corporate/Financial News
Language:English
12/05/2018
Bristol-Myers Squibb to Announce Results for Fourth Quarter 2018 on January 24
Term:Corporate/Financial News
Language:English
12/03/2018
Bristol-Myers Squibb to Transfer $3.8 billion in U.S. Pension Liabilities
Term:Corporate/Financial News
Language:English
11/29/2018
Bristol-Myers Squibb to Highlight New Data from Broad Oncology Portfolio at the 60th American Society of Hematology Annual Meeting
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm